Abstract Number: 0996 • ACR Convergence 2020
Bacteria-Derived Indole Drives Autoimmune Arthritis by Altering B Cell Glycosylation of Autoantibodies
Background/Purpose: Background: Dysbiosis of gut bacterial communities in rheumatoid arthritis (RA) is a noted phenomenon in both murine models and human patients; however, the mechanisms…Abstract Number: 1144 • ACR Convergence 2020
Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic
Background/Purpose: Patients with autoimmune rheumatic diseases may be particularly concerned about COVID-19. We aimed to assess concerns and associated health behaviors of patients with autoimmune…Abstract Number: 1409 • ACR Convergence 2020
Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
Background/Purpose: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor (ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill the ACR-EULAR…Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…Abstract Number: 1916 • ACR Convergence 2020
KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model
Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…Abstract Number: 0235 • ACR Convergence 2020
Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study
Background/Purpose: B-cell activating factor (BAFF) and inducible costimulator ligand (ICOSL) are implicated in autoimmune disease pathogenesis, and clinical findings support their utility as drug targets…Abstract Number: 0502 • ACR Convergence 2020
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…Abstract Number: 0997 • ACR Convergence 2020
Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes,…Abstract Number: 1166 • ACR Convergence 2020
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
Background/Purpose: Coatomer protein complex subunit α (COPA) syndrome is a rare genetic multisystem autoimmune disorder inherited in an autosomal dominant manner. Onset typically occurs in…Abstract Number: 1411 • ACR Convergence 2020
CD8+ T Cell Subsets and Immune Checkpoint Profiles in Ankylosing Spondylitis Implicate Dysregulation of Cytotoxic T Lymphocytes (CTL)
Background/Purpose: Ankylosing Spondylitis (AS) is characterized by chronic inflammation which underlies the pain and precedes spinal ankylosis. The strongest genetic association with AS is the…Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…Abstract Number: 1917 • ACR Convergence 2020
In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with anti-cN1A Antibody Independently of the Myositis Subgroups
Background/Purpose: Myositis are characterized by weakness and muscle inflammation. They encompass heterogeneous conditions, which include dermatomyositis (DM), inclusion body myositis (IBM) and polymyositis (PM) according…Abstract Number: 0286 • ACR Convergence 2020
An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
Background/Purpose: SLE is a chronic and debilitating disease; in the USA with an estimated incidence of 3-10 per 100,000 people and currently affecting an estimated…Abstract Number: 0511 • ACR Convergence 2020
ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses
Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 80
- Next Page »